Kymera's Revenue Reappearance Could Redefine What Analysts Expected From This Degrader Story

Kymera Therapeutics (NASDAQ: KYMR) reports second quarter 2026 earnings before market open on August 5, 2026, with analysts expecting a loss of $-0.64 per share. The clinical-stage biopharmaceutical company has delivered mixed results recently, posting a surprise beat last quarter after three consecutive misses, leaving investors to assess whether the Q1 improvement signals a sustainable turnaround or a temporary reprieve. With the stock trading at $104.39 and analyst price targets implying 21% upside, the report will test whether Kymera's degrader platform can maintain momentum in a volatile biotech environment.

Part 1: Earnings Preview

Kymera Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of oral small molecule degrader medicines targeting immunological diseases. The company's proprietary platform leverages targeted protein degradation to address diseases previously considered undruggable, positioning it at the forefront of a transformative therapeutic approach.

Kymera reports Q2 2026 earnings before market open on August 5, 2026, with the consensus estimate calling for a loss of $-0.64 per share on revenue of $32.16 million. The company most recently reported Q1 2026 earnings of $-0.71 per share, beating estimates by 20.22% and marking a significant reversal after three straight quarters of disappointing results. Year-over-year, the Q2 estimate of $-0.64 represents a 32.63% improvement compared to the $-0.95 loss reported in Q2 2025, suggesting meaningful progress in the company's path toward profitability.

Three key themes define this earnings story:

Clinical Pipeline Advancement: Investors will scrutinize updates on Kymera's lead programs and any new data readouts that could validate the degrader platform's commercial potential. Progress in moving candidates through clinical trials remains the primary value driver for the company.

Revenue Trajectory and Partnership Economics: After Q1 revenue of $34.37 million dramatically exceeded the $8.27 million estimate by over 315%, the market will assess whether Q2's $32.16 million forecast reflects sustainable collaboration revenue or whether Q1 represented a one-time milestone payment event.

Cash Runway and Operational Efficiency: With consensus estimates projecting continued losses through 2027, investors will focus on burn rate, cash position, and management's ability to extend the runway while advancing multiple programs through expensive clinical development stages.

Analyst commentary ahead of the release reflects cautious optimism, with 21 of 25 analysts rating the stock a Strong Buy and price targets ranging from $97 to $155. The bullish stance centers on Kymera's differentiated technology platform and the potential for its degrader approach to address large unmet medical needs in immunology.

Part 2: Historical Earnings Performance

Kymera's recent earnings history reveals a company in transition, with performance swinging between significant misses and occasional beats. Over the past four quarters, the company has missed estimates three times and beaten once, with surprises ranging from -26.76% to +20.22%.

The pattern shows deteriorating performance through mid-2025 and into early 2026, followed by a sharp reversal. Q2 2025 delivered a -14.46% miss with $-0.95 versus $-0.83 expected, followed by an even larger -26.76% miss in Q3 2025 ($-0.90 vs. $-0.71 estimate). Q4 2025 continued the negative trend with a -25.97% miss ($-0.97 vs. $-0.77 estimate), marking three consecutive quarters of underperformance.

The most recent quarter broke this pattern decisively: Q1 2026 posted $-0.71 versus the $-0.89 estimate, a +20.22% beat that represented the strongest positive surprise in the available history. This reversal suggests either improved operational execution, favorable timing of partnership milestones, or both. The question heading into Q2 is whether this beat signals a sustainable inflection point or represents an isolated quarter driven by non-recurring revenue events.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Kymera typically reports before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price action around Kymera earnings shows significant volatility, with an average absolute Day 0 move of 4.43% and intraday ranges averaging 11.66%. The most dramatic reaction came in Q4 2024 (February 2025), when the stock plunged -14.45% on earnings day with an intraday range of 17.32%, reflecting severe disappointment with results. More recently, Q4 2025 (February 2026) saw a +4.80% Day 0 gain with a 13.42% intraday range, while the most recent Q1 2026 report produced a modest -0.54% Day 0 move despite the earnings beat.

Day +1 follow-through averages 3.21% in absolute terms with 6.60% average ranges, suggesting continued volatility into the second session. The pattern indicates investors should prepare for substantial price swings regardless of whether results beat or miss, with the options market's 6.43% expected move falling below the historical 11.66% Day 0 range average but above the 4.43% Day 0 move average.

Part 2.2: Options Market Expected Move

The options market is pricing a 6.43% expected move (±$6.72, range $97.68–$111.11) for the August 21 expiration, which sits between the historical 4.43% average Day 0 move and the 11.66% average Day 0 range. This suggests options traders are anticipating above-average directional movement but below-average intraday volatility compared to Kymera's recent earnings history.

Part 3: What Analysts Are Saying

Analyst sentiment on Kymera remains overwhelmingly bullish despite recent volatility, with 21 of 25 analysts rating the stock a Strong Buy, zero rating it Hold, and 4 rating it a Moderate Buy. The average recommendation of 4.68 sits firmly in Strong Buy territory on the 1–5 scale, though sentiment has deteriorated slightly from 4.79 one month ago as one analyst downgraded from Strong Buy to Moderate Buy and two shifted from Moderate Buy to Hold.

The consensus price target of $126.83 implies 21.5% upside from the current $104.39 price, with the range spanning from a low of $97.00 (7% downside) to a high of $155.00 (48% upside). This wide target range reflects divergent views on the timeline and probability of clinical and commercial success, though even the most conservative target sits near current levels, suggesting limited downside risk in the analyst community's view.

The recent sentiment deterioration appears tactical rather than fundamental, likely reflecting profit-taking after the stock's strong run above its 50-day, 100-day, and 200-day moving averages rather than concerns about the underlying business or pipeline. The concentration of Strong Buy ratings indicates analysts view any near-term weakness as a buying opportunity ahead of potential clinical catalysts.

Part 4: Technical Picture

Kymera's technical setup heading into earnings shows mixed signals with the stock consolidating after a strong advance. The Barchart Technical Opinion currently registers 80% Buy, down from 88% Buy one week ago and 100% Buy one month ago, indicating some near-term momentum loss despite the overall bullish posture.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal reflects recent consolidation and reduced momentum as the stock digests gains
• Medium-term (100% Buy): Strong buy signal indicates the intermediate trend remains firmly positive with upside momentum intact
• Long-term (100% Buy): Strong buy signal confirms the broader uptrend is well-established and supportive

Trend Characteristics: The Strong trend with Strengthening direction suggests Kymera maintains a robust technical foundation despite short-term consolidation, with the longer timeframes providing support for the overall bullish structure heading into the earnings event.

The stock is currently trading at $104.39, positioned above its 5-day ($104.07), 50-day ($98.93), 100-day ($91.05), and 200-day ($82.59) moving averages, but below its 10-day ($106.79) and 20-day ($110.56) averages. This configuration suggests a healthy pullback within a longer-term uptrend, with the 50-day average at $98.93 representing the first major support level. The stock's position below its 20-day average indicates near-term resistance around $110.56, which coincidentally aligns with the options market's upper expected move boundary of $111.11. The overall technical setup is moderately supportive for earnings, with the longer-term trend providing a cushion against downside volatility while recent consolidation has reduced the risk of an overextended rally reversing sharply on any disappointment.